Truist Securities Maintains Buy on Edwards Lifesciences, Raises Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reaffirmed a Buy rating on Edwards Lifesciences (NYSE:EW) and increased the price target from $76 to $78.
December 11, 2023 | 4:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Richard Newitter maintains a Buy rating on Edwards Lifesciences and raises the price target from $76 to $78, indicating a positive outlook on the stock.
The increase in price target by Truist Securities suggests a positive sentiment towards Edwards Lifesciences' stock performance. As price targets often influence investor expectations and can lead to price movements, this revised target is likely to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100